---
title: "Core-shell electrospun nanofibers co-delivering bacteriophage JG004 and aztreonam for Pseudomonas"
id: "pubmed-42486205"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42486205"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42486205/"
doi: "10.1016/j.ijpharm.2026.127224"
published_at: "2026-09-05T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Core-shell electrospun nanofibers co-delivering bacteriophage JG004 and aztreonam for Pseudomonas
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42486205
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42486205/)
- **DOI:** [10.1016/j.ijpharm.2026.127224](https://doi.org/10.1016%2Fj.ijpharm.2026.127224)
- **Published At:** 2026-09-05T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The study addresses challenges of antimicrobial resistance in chronic wound care, where poor perfusion and biofilm-embedded bacteria reduce antibiotic efficacy. - The authors developed a **core-shell nanofiber** platform produced by **electrospinning** to co-deliver a lytic **bacteriophage** (JG004) and the β-lactam antibiotic **aztreonam** while spatially separating the agents within the fiber matrix. - The fibers are mechanically robust and preserve phage viability for at least **28 days**, while enabling rapid release of both antimicrobials. - The core-shell architecture reduces phage exposure to environmental and oxidative stressors compared with unprotected formulations. - In vitro testing showed pronounced **phage-antibiotic synergy**, producing up to **99% bacterial reduction** of **Pseudomonas aeruginosa** and outperforming single-agent treatments against both planktonic and biofilm-associated bacteria. - The delivery system is modular, permitting integration of alternate phage-antibiotic combinations to match patient-specific pathogens and resistance profiles. - The platform aims to combine sustained antimicrobial performance with clinical adaptability, supporting potential translation of phage-based strategies into modern wound care. - Details on in vivo testing, regulatory considerations, exact fiber compositions, manufacturing scale-up, and long-term safety were not reported in the abstract and would require consultation of the full text for confirmation.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42486205/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42486205%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42486205/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42486205/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42486205/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42486205/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42486205/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42486205%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42486205%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42486205/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42486205/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42486205/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42486205/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Elsevier Science full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-elsevieroa.png) Elsevier Science ](https://linkinghub.elsevier.com/retrieve/pii/S0378-5173\(26\)00672-1 "See full text options at Elsevier Science") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42486205/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42486205/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42486205/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42486205/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42486205/#conflict-of-interest) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42486205/#similar) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42486205/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42486205/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42486205/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42486205/#linkout) Title & authors Abstract Conflict of interest statement Similar articles MeSH terms Substances Related information LinkOut - more resources Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) . 2026 Sep 5:702:127224. doi: 10.1016/j.ijpharm.2026.127224. Epub 2026 Jul 22. # Co-delivery of therapeutic bacteriophages and aztreonam via core-shell electrospun fibers for synergistic action against Pseudomonas aeruginosa infections [Johannes Most](https://pubmed.ncbi.nlm.nih.gov/?term=Most+J&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#full-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Alexandra Hübl](https://pubmed.ncbi.nlm.nih.gov/?term=H%C3%BCbl+A&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#full-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Viktoria Planz](https://pubmed.ncbi.nlm.nih.gov/?term=Planz+V&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#full-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Maike Windbergs](https://pubmed.ncbi.nlm.nih.gov/?term=Windbergs+M&cauthor_id=42486205)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#full-view-affiliation-2 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: windbergs@em.uni.frankfurt.de.") Affiliations Expand ### Affiliations * 1 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. * 2 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: windbergs@em.uni.frankfurt.de. * PMID: **42486205** * DOI: [ 10.1016/j.ijpharm.2026.127224 ](https://doi.org/10.1016/j.ijpharm.2026.127224) Free article Item in Clipboard # Co-delivery of therapeutic bacteriophages and aztreonam via core-shell electrospun fibers for synergistic action against Pseudomonas aeruginosa infections Johannes Most et al. Int J Pharm. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Int J Pharm Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Int+J+Pharm%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int+J+Pharm%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) . 2026 Sep 5:702:127224. doi: 10.1016/j.ijpharm.2026.127224. Epub 2026 Jul 22. ### Authors [Johannes Most](https://pubmed.ncbi.nlm.nih.gov/?term=Most+J&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#short-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Alexandra Hübl](https://pubmed.ncbi.nlm.nih.gov/?term=H%C3%BCbl+A&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#short-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Viktoria Planz](https://pubmed.ncbi.nlm.nih.gov/?term=Planz+V&cauthor_id=42486205)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#short-view-affiliation-1 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany."), [Maike Windbergs](https://pubmed.ncbi.nlm.nih.gov/?term=Windbergs+M&cauthor_id=42486205)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42486205/#short-view-affiliation-2 "Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: windbergs@em.uni.frankfurt.de.") ### Affiliations * 1 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. * 2 Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: windbergs@em.uni.frankfurt.de. * PMID: **42486205** * DOI: [ 10.1016/j.ijpharm.2026.127224 ](https://doi.org/10.1016/j.ijpharm.2026.127224) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract The global rise of antimicrobial resistance poses a persistent challenge in chronic wound care, where limited perfusion and biofilm-embedded bacterial communities severely restrict the efficacy of conventional antibiotics. Despite renewed interest and promising approaches, bacteriophage-based therapy remains constrained by intrinsic phage susceptibility to complex wound environments and the emergence of phage resistance. While synergistic pairings of phages and antibiotics offer a compelling strategy to counteract these limitations, the lack of systems capable of protecting and delivering respective pairs continues to impair clinical translation. To address these challenges, we developed an electrospun nanofiber-based co-delivery platform that spatially separates the lytic bacteriophage JG004 and the β-lactam antibiotic aztreonam within a protective core-shell matrix. The nanofibers exhibit high mechanical robustness, maintain phage viability for at least 28 days, and enable rapid release of both antimicrobials, while reducing exposure to environmental and oxidative stresses. In vitro assays revealed pronounced phage-antibiotic synergy, achieving up to 99% bacterial reduction of Pseudomonas aeruginosa, outperforming the corresponding monotherapies in treatment of both planktonic and biofilm-associated bacteria. Additionally, the modular architecture of our delivery system enables flexible integration of alternative phage-antibiotic pairings, enabling rapid adaptation to patient-specific pathogens and resistance profiles. By combining sustained antimicrobial performance with a clinically adaptable delivery system, this nanofiber platform offers a promising route towards personalized infection management and supports the clinical integration of phage-based strategies into modern wound care. **Keywords:** Biofilm infection; Core–shell nanofibers; Electrospinning; Localized anti-infective therapy; Phage-antibiotic-synergy; Pseudomonas aeruginosa. Copyright © 2026 The Authors. Published by Elsevier B.V. All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ## Similar articles * [ Development of spray-dried phage-aztreonam microparticles for inhalation therapy of Pseudomonas aeruginosa lung infections. ](https://pubmed.ncbi.nlm.nih.gov/41407212/) Hübl A, Most J, Hauß C, Planz V, Windbergs M.Hübl A, et al.Eur J Pharm Biopharm. 2026 Feb;219:114966. doi: 10.1016/j.ejpb.2025.114966. Epub 2025 Dec 15.Eur J Pharm Biopharm. 2026.PMID: 41407212 * [ Bacteriophage therapy for antimicrobial-resistant, biofilm‑associated diabetic foot infection: delivery routes, phage antibiotic synergy, and practical wound‑care integration. ](https://pubmed.ncbi.nlm.nih.gov/42611076/) Irbaz M, Hamood Z, Shahid S, Ghufran A, Ajmal A, Rafiq I.Irbaz M, et al.Arch Microbiol. 2026 Aug 18;208(11):580. doi: 10.1007/s00203-026-05134-8.Arch Microbiol. 2026.PMID: 42611076Review. * [ Dual phage-incorporated electrospun polyvinyl alcohol-eudragit nanofiber matrix for rapid healing of diabetic wound infected by Pseudomonas aeruginosa and Staphylococcus aureus. ](https://pubmed.ncbi.nlm.nih.gov/38980574/) Suchithra KV, Hameed A, Surya S, Mahammad S, Arun AB.Suchithra KV, et al.Drug Deliv Transl Res. 2025 Mar;15(3):1092-1108. doi: 10.1007/s13346-024-01660-4. Epub 2024 Jul 9.Drug Deliv Transl Res. 2025.PMID: 38980574 * [ Combinations of Bacteriophage Are Efficacious against Multidrug-Resistant _Pseudomonas aeruginosa_ and Enhance Sensitivity to Carbapenem Antibiotics. ](https://pubmed.ncbi.nlm.nih.gov/39066163/) Kovacs CJ, Rapp EM, Rankin WR, McKenzie SM, Brasko BK, Hebert KE, Bachert BA, Kick AR, Burpo FJ, Barnhill JC.Kovacs CJ, et al.Viruses. 2024 Jun 21;16(7):1000. doi: 10.3390/v16071000.Viruses. 2024.PMID: 39066163Free PMC article. * [ A review of phage therapy for drug-resistant Pseudomonas aeruginosa infections. ](https://pubmed.ncbi.nlm.nih.gov/41412007/) Yu X, Zhang J, Li X, Li G, Lu X, Shi Y, Lin W, Wang X, Zhang W, Tong Y, Li M, Xie L, Yao M.Yu X, et al.Microbiol Res. 2026 Apr;305:128417. doi: 10.1016/j.micres.2025.128417. Epub 2025 Dec 16.Microbiol Res. 2026.PMID: 41412007Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42486205) ## MeSH terms * Anti-Bacterial Agents* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Bacterial+Agents%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Bacterial+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Anti-Bacterial Agents* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Bacterial+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Anti-Bacterial+Agents) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Aztreonam* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aztreonam%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aztreonam) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Aztreonam* / pharmacology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Aztreonam%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Aztreonam) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Bacteriophages* Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Bacteriophages%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Bacteriophages) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Biofilms / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Biofilms%2Fdrug+effects%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Biofilms) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Drug Delivery Systems Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Delivery+Systems%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Delivery+Systems) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Nanofibers* / administration & dosage Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nanofibers%2Fadministration+and+dosage%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Nanofibers) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Nanofibers* / chemistry Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Nanofibers%2Fchemistry%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Nanofibers) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Phage Therapy* / methods Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Phage+Therapy%2Fmethods%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Phage+Therapy) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Pseudomonas Infections* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pseudomonas+Infections%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pseudomonas+Infections) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Pseudomonas Infections* / microbiology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pseudomonas+Infections%2Fmicrobiology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pseudomonas+Infections) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Pseudomonas Infections* / therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pseudomonas+Infections%2Ftherapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pseudomonas+Infections) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) * Pseudomonas aeruginosa* / drug effects Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pseudomonas+aeruginosa%2Fdrug+effects%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pseudomonas+aeruginosa) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42486205/) ## Substances * Anti-Bacterial Agents Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anti-Bacterial+Agents%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https
## Related Clinical Research

- [WHO validates Bhutan for eliminating dog-transmitted human rabies](https://medichelpline.com/clinical-feed/who-0-0-who-validates-bhutan-for-eliminating-dog-transmitted-human-rabies.md)
- [Infection prevention and control implementation during COVID-19 in sub-Saharan Africa: multination](https://medichelpline.com/clinical-feed/bmj-open-0-infection-prevention-and-control-measures-during-the-covid-19-pandemic-in-sub.md)
- [High AUROC can hide threshold failure in sepsis transcriptomic classifiers: preprocessing stabilit](https://medichelpline.com/clinical-feed/plos-one-13-high-auroc-can-mask-decision-failure-in-sepsis-transcriptomic-classifiers.md)
- [HPV and HPV vaccine awareness in Indigenous communities of Northwest Territories, Canada](https://medichelpline.com/clinical-feed/plos-one-12-human-papillomavirus-hpv-and-hpv-vaccine-awareness-in-indigenous-communities-in.md)
- [Serotype-specific dengue transmission intensity in Mexico (2016–2023): national modelling analysis](https://medichelpline.com/clinical-feed/plos-medicine-1-overall-and-serotype-specific-dengue-virus-transmission-intensity-in-mexico.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.